Q2 FY2026 · ended Jun 30, 2026 · Revenue $22,000, -97.0% YoY · Filed Aug 6, 2026
Celldex Therapeutics, Inc. (CLDX) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $22,000 and a net loss of $73.5 million. Free cash flow was -$60.6 million. As of Jun 30, 2026 it held $717.6 million in cash and investments and $4.9 million in total debt.
Revenue
$22,000
-97.0% vs year-ago quarter
Net income
$-73.50M
-29.9% vs year-ago quarter
Operating cash flow
$-57.41M
-30.5% vs year-ago quarter
Free cash flow
$-60.59M
-35.4% vs year-ago quarter
EPS
$-0.94
-10.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
78.53M
+18.3% vs year-ago quarter
Net cash
$712.68M
Q2 FY2026
Operating margin
-206220.3%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CLDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hampton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 744218
- Former names
- AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $22,000 | $15,000 | $121,000 | $0 | $730,000 |
| Operating income | -$80.6M | -$84.4M | -$87.2M | -$73.6M | -$63.9M |
| Net income | -$73.5M | -$78.7M | -$81.3M | -$67.0M | -$56.6M |
| Diluted EPS | -$0.94 | -$1.18 | -$0.31 | -$1.01 | -$0.85 |
| Operating cash flow | -$57.4M | -$65.6M | -$63.9M | -$48.6M | -$44.0M |
| Free cash flow | -$60.6M | -$67.2M | -$65.2M | -$49.1M | -$44.7M |
| Total assets | $782.3M | $511.3M | $583.0M | $648.4M | $692.4M |
| Total liabilities | $67.8M | $55.0M | $55.8M | $50.1M | $37.0M |
| Stockholders' equity | $714.6M | $456.2M | $527.2M | $598.4M | $655.4M |
| Cash and investments | $717.6M | $451.5M | $518.6M | $583.2M | $630.3M |
| Total debt | $4.9M | $1.9M | $2.3M | $2.6M | $3.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 15, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 26, 2026 | Jun 25, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 1000 Celldex Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.